<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105505</url>
  </required_header>
  <id_info>
    <org_study_id>003-16-BRZ</org_study_id>
    <nct_id>NCT03105505</nct_id>
  </id_info>
  <brief_title>Prospective-Randomized Trial Assessing the Efficacy of Permethrin 5% for Demodex - Blepharitis Treatment in Comparison to Fucithalmic (Fusidic Acid 1%) and Synthomycine 5%</brief_title>
  <official_title>The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective -Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barzilai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barzilai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the effect of Permethrin 5% treatment on Signs and symptoms of
      Demodex-blepharitis in comparison to Synthomycine 5% and Fucithalmic (fusidic acid 1%) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3 arms study. 75 patient total, 25 patients in each group.

      Group A (study group) patients will apply facially Permethrin 5% every night for 3 months.

      Group B patients will apply on the eyelids Fusidic acid 1% every night for 3 months.

      Group C patients will apply on the eyelids Synthomycine 5% every night for 3 months

      Follow up Evaluation will be made after one week, one month, two months, three months, 4
      months and half a year.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">April 28, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in demodex infestation in group A (permethrin 5%).</measure>
    <time_frame>2 months</time_frame>
    <description>significant decrease in demodex infestation in comparison to group B and C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in symptoms and complaints in group A.</measure>
    <time_frame>2 months</time_frame>
    <description>OSDI Questionnaires that describe the severity of the ocular surface disease condition are filled in each visit.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Inflammation of the Eyelids</condition>
  <arm_group>
    <arm_group_label>Permethrin 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synthomycine 5%,</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contains chloramphenicol 5%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fusidic Acid 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permethrin 5%</intervention_name>
    <description>Facial skin application once a night for 3 months.</description>
    <arm_group_label>Permethrin 5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synthomycine 5%</intervention_name>
    <description>Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.</description>
    <arm_group_label>Synthomycine 5%,</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fusidic Acid 1% M/R Eye Drops</intervention_name>
    <description>viscous eye drops application once a night for 3 months.</description>
    <arm_group_label>Fusidic Acid 1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Adult (Age â‰¥18Y) individuals clinically diagnosed with Demodex- blepharitis.

        Exclusion Criteria:

        - Known sensitivity to all study medications or components. Pregnant women and individuals
        deemed unfit to provide informed consent. Systemic steroid use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashqelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Israel</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>March 28, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barzilai Medical Center</investigator_affiliation>
    <investigator_full_name>Igor Kaiserman</investigator_full_name>
    <investigator_title>Prof Igor Kaiserman</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Permethrin</mesh_term>
    <mesh_term>Fusidic Acid</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
